Artemether/Lumefantrine

蒿甲醚/本芴醇

Report date: 2025/07/08 17:24:57
First In Class

Base Information

Drug NameArtemether/Lumefantrine
Drug Alias NameArtemether-Lumefantrine本芴醇蒿甲醚Lumefantrine/Artemether本芴醇/蒿甲醚Artemether and Lumefantrine +[17] 
ClassificationSmall molecules
Mechanisms of ActionSarcoplasmic/endoplasmic reticulum calcium ATPase 2 inhibitorsSarcoplasmic/endoplasmic reticulum calcium ATPase 1 inhibitors
TargetsSarcoplasmic/endoplasmic reticulum calcium ATPase 2Sarcoplasmic/endoplasmic reticulum calcium ATPase 1
Therapy Area/IndicationsMalaria, VivaxMalaria, FalciparumMalaria
Global Approved IndicationsMalaria
Approved Indications in ChinaMalaria
Original Approved Country/TerritoryMainland China
Original Approved Date1992/01/01
Country/TerritoryBeninUnited StatesTogo +[15] 
CombinationsYes ArtemetherLumefantrine
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma AgKpc Pharmaceuticals Inc
Inactive CompaniesUniversity Of OxfordFriends Of The University Of Khartoum
Active IndicationsMalaria
Inactive IndicationsMalaria, VivaxMalaria, Falciparum

Other Information

ATC CodeP01B
Related LinksWikipediaKEGG